on 06-16-2022 12:30 PM - edited on 08-10-2022 07:48 AM by GeorgeTFS
As demonstrated by the development of the COVID-19 vaccine, large RNA (including mRNA) has emerged as a new class of therapeutics. However, developing analytical methods for the analysis of mRNA therapeutics has its share of challenges, including:
There’s currently significant demand for the development of new and improved analytical methods for the characterization of mRNA therapeutics.
Fortunately, mass spectrometry can help today’s labs develop an automated, high-throughput workflow for the rapid characterization and direct sequence mapping of large RNA and mRNA molecules. In a recent publication on Analytical Chemistry, Prof. Mark Dickman at the University of Sheffield described a complete workflow that achieves routine comprehensive sequence coverage from a single analysis while overcoming challenges associated with digestion, oligonucleotide separation and identification.
This workflow enables you to
Download article on Analytical Chemistry
Watch the on-demand webinar
Website: mRNA Vaccine Characterization
Blog: The mRNA Revolution: How the Race for a COVID-19 Vaccine Has Brought mRNA Therapeutics to Ever...
Article: The expanding role of mass spectrometry in the field of vaccine development
On-Demand Webinar: Profiling the HLA-II Immunopeptidome of SARS-CoV-2 Spike Glycoprotein Using Mass ...